Associations of Clinical and Molecular Characteristics with the Response to Immune Checkpoint Blockade in Advanced Gastric Cancers
Xiaoqing Xu(Zhejiang Chinese Medical University), Qi Xu(China Jiliang University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing‐Jing Li(Shanghai Institute of Nutrition and Health), Xiaowan Tang(Taizhou First People's Hospital), Cong Luo(Central South University), Lei Chen(Zhuzhou Central Hospital), Wei Wu(Tianjin University), Yuan Xing(117th Hospital of People's Liberation Army), Qing Wei(Chinese Academy of Sciences), Xiu Zhu(Zhejiang Cancer Hospital), Wangxia Lv(Zhejiang Cancer Hospital), Yiding Gao(Zhejiang Chinese Medical University), Jinlin Hu(Zhejiang Cancer Hospital), Lingnan Zhang(Zhejiang Cancer Hospital)
Cited by 3
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934